Sulfonylureas may increase risk of death in type 2 diabetes patients

09/26/2013 | U.S. News & World Report

British researchers found type 2 diabetes patients who used sulfonylureas as an initial treatment had a 58% higher risk of all-cause mortality compared with those who were on metformin monotherapy. While more data are needed, the results suggest using sulfonylureas as first-line monotherapy "should be reconsidered," researchers reported at the European Association for the Study of Diabetes meeting.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC